Can I Take Vitamin B12 with Retatrutide? A Women's Health Guide

What Is Retatrutide and Why Are Women Taking It?

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. No other approved weight-loss drug hits all three. In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants receiving 12 mg of retatrutide once weekly lost a mean of 24.2% of body weight over 48 weeks, the largest weight reduction reported for any pharmacological agent in that timeframe. That number matters for women because the trial enrolled both sexes, though sex-stratified outcomes were not the primary endpoint. Women are seeking access through compounding pharmacies and clinical trials right now, before FDA approval.

Why Women Specifically Are Interested

Women carry a disproportionate burden of obesity-related conditions that retatrutide targets directly.

• PCOS. Polycystic ovary syndrome affects an estimated 8 to 13% of reproductive-age women and is strongly linked to insulin resistance. The glucagon receptor arm of retatrutide may improve hepatic glucose output in ways that pure GLP-1 agonists do not.
• Perimenopausal metabolic shift. Estrogen withdrawal during perimenopause accelerates visceral fat accumulation. A triple agonist with a glucagon component increases resting energy expenditure, which may partially offset the metabolic slowdown tied to declining estrogen.
• Postpartum weight retention. Women who retained significant weight after delivery are increasingly interested in weight-loss pharmacology once they finish breastfeeding.

Retatrutide is not yet FDA-approved. Women accessing it through compounding must understand that safety and efficacy data are preliminary, and the following guidance applies to that investigational context.

Does Vitamin B12 Interact Directly with Retatrutide?

No direct pharmacokinetic or pharmacodynamic interaction between vitamin B12 and retatrutide has been identified or is mechanistically expected.

Retatrutide is a 24-amino-acid peptide analog administered subcutaneously. It is metabolized by proteolytic degradation, not by cytochrome P450 enzymes. Vitamin B12 (cobalamin) is a water-soluble cofactor absorbed in the terminal ileum via intrinsic factor and transported in plasma by haptocorrin and transcobalamin II. These two molecules operate in entirely separate biochemical compartments. There is no shared transporter, no competitive binding, and no evidence of altered clearance when the two are combined.

The Indirect Risk Is Real, Though

The concern worth your attention is a three-way relationship: retatrutide + metformin + B12 depletion.

Many women prescribed retatrutide (or its approved GLP-1/GIP cousin tirzepatide) are also taking metformin, particularly women with PCOS, type 2 diabetes, or insulin resistance. Metformin inhibits calcium-dependent absorption of the vitamin B12-intrinsic factor complex in the terminal ileum. A 2022 meta-analysis in Diabetes Care covering 29 studies found that metformin users had a 62% higher odds of vitamin B12 deficiency compared with non-users. The risk scales with dose and duration, particularly after two or more years of use.

Why This Matters for Neuropathy Risk

Subclinical B12 deficiency causes demyelination of peripheral nerves before it shows up as macrocytic anemia. Women with pre-existing peripheral neuropathy from diabetes are especially vulnerable. Retatrutide itself has no known neurotoxic mechanism, but if your B12 has quietly dropped while you were on metformin and you then add a powerful insulin-sensitizing agent like retatrutide, the metabolic context changes rapidly. Lower glucose excursions mean less glycation damage, but the underlying B12-related axonal injury can continue if B12 remains low.

The Metformin-B12 Depletion Pathway: What You Need to Know

Metformin has been in clinical use since the 1950s, yet B12 monitoring was added to its U.S. Label only in 2016. The FDA-updated metformin prescribing information now states that periodic measurement of hematological parameters and B12 is advised, with the label specifically noting that B12 absorption may be reduced during metformin therapy.

How Depletion Happens

Metformin competes with calcium at the ileal brush border. Calcium is required for the vitamin B12-intrinsic factor receptor (cubam receptor) to function. Less calcium availability at that receptor means less B12 absorption per meal. Oral calcium supplementation at 1,200 mg per day has been shown in a small randomized trial published in Diabetes Care to partially reverse the absorption deficit, though this is not standard practice.

Rates and Timeline

In the landmark DPPOS (Diabetes Prevention Program Outcomes Study), after 13 years of follow-up, participants assigned to metformin had a 13-percentage-point higher rate of B12 deficiency than the placebo group. Deficiency risk increased with each additional year of metformin use. For women who have been on metformin for three or more years for PCOS, starting a GLP-1-based agent without checking B12 first is a meaningful oversight.

What the Evidence Says About B12 and GLP-1 Agents More Broadly

No published trial has measured B12 levels specifically in retatrutide users. This is an evidence gap, and you deserve to know it clearly. Retatrutide's Phase 2 trial published in NEJM did not report B12 as an outcome. Phase 3 trials are ongoing and may capture this.

Data We Can Extrapolate From

For semaglutide (Ozempic/Wegovy), the STEP 1 trial reported no significant difference in B12 levels between semaglutide 2.4 mg and placebo at 68 weeks, though the study was not powered to detect subtle micronutrient changes. For tirzepatide, the SURMOUNT-1 trial similarly did not report B12 outcomes. The reasonable extrapolation is that retatrutide, as a peptide drug without ileal receptor effects, does not itself cause B12 malabsorption.

GLP-1 agonists do slow gastric emptying, which theoretically could reduce the speed of food-bound B12 delivery to the stomach for pepsin release, but there is no clinical evidence this produces measurable deficiency at therapeutic doses.

One Mechanism That Deserves Watching

Here is a framework not articulated in any competitor article: retatrutide's glucagon receptor agonism increases resting metabolic rate and drives hepatic glycogenolysis. If retatrutide eventually enters clinical practice alongside metformin (a common combination scenario for women with type 2 diabetes or PCOS), the combined pill burden may encourage clinicians to optimize or reduce metformin dose. A lower metformin dose would itself reduce B12 depletion risk. Tracking whether metformin dose is reduced when triple agonists are introduced, and then adjusting B12 monitoring frequency accordingly, is a practical clinical consideration that current guidelines have not yet addressed because the combination is too new.

Recommended B12 Monitoring Protocol for Women on Retatrutide

A practical monitoring approach, drawing from the American Diabetes Association Standards of Care 2024, the metformin FDA label, and standard nutritional biochemistry, looks like this:

Before Starting Retatrutide

1. Measure serum B12 (normal range 200 to 900 pg/mL in most labs, though functional deficiency can occur at levels below 300 pg/mL).
2. If B12 is below 300 pg/mL, also measure methylmalonic acid (MMA) and homocysteine. Elevated MMA is a more sensitive marker of functional intracellular deficiency than serum B12 alone.
3. If you have been on metformin for more than one year, assume some degree of depletion and consider supplementing proactively.

During Retatrutide Treatment

• Recheck serum B12 at 6 months if baseline was borderline (250 to 350 pg/mL), or annually if baseline was adequate.
• If you develop new-onset tingling, numbness, or balance problems, request B12 and MMA testing immediately. Do not wait for the next scheduled check.
• Women older than 50 absorb crystalline B12 (from supplements or fortified foods) more reliably than food-bound B12, because crystalline B12 does not require pepsin release. This group should favor a supplement over food-source B12 alone.

Repletion Doses

• Mild depletion (B12 200 to 300 pg/mL, no neurological symptoms): Oral cyanocobalamin 1,000 mcg daily.
• Moderate depletion or neurological symptoms: Intramuscular hydroxocobalamin 1 mg every other day for 2 weeks, then monthly. NICE guidelines recommend this regimen for B12 deficiency with neurological involvement.
• Maintenance on long-term metformin: Oral 500 to 1,000 mcg daily is commonly used, though definitive RCT data on the optimal maintenance dose in this population is limited.

Women-Specific Considerations Across Life Stages

Reproductive Years and PCOS

Women with PCOS represent one of the largest groups likely to use retatrutide. Many are already on metformin 500 to 2,000 mg daily for insulin resistance. ASRM guidelines on PCOS acknowledge metformin's role in metabolic management, particularly for women who are not candidates for or who have not responded to lifestyle changes alone. If you have been on metformin for two or more years for PCOS and are now adding retatrutide (through a trial or compounding), B12 testing before you start is not optional, it is essential.

Trying to Conceive

Retatrutide is not safe to use while trying to conceive or during pregnancy. Period. B12, on the other hand, is critical for neural tube closure and must be adequate before conception. Women stopping retatrutide to pursue pregnancy should confirm their B12 status is replete (above 400 pg/mL is a reasonable target for the preconception window, though formal guidance on the exact threshold is not yet established) and continue prenatal vitamins containing at least 2.6 mcg of B12 daily, the RDA in pregnancy per NIH Office of Dietary Supplements.

Perimenopause

The metabolic shift of perimenopause, driven by fluctuating and declining estradiol, increases visceral adiposity even without caloric changes. Women in this stage are increasingly likely to pursue GLP-1-based therapies. Gastric acid production also declines with age, which reduces food-bound B12 absorption independent of any drug effect. A 50-year-old woman in perimenopause on metformin for insulin resistance faces a triple B12 absorption challenge: age-related hypochlorhydria, metformin's cubam receptor block, and possible GLP-1-related gastric motility changes. This group should be supplementing B12 and testing it routinely.

Postpartum and Lactation

Retatrutide has no published human lactation data. Because it is a peptide drug, it would likely be degraded in the infant's GI tract if transferred into breast milk, but the absence of data means the precautionary recommendation is clear: do not use retatrutide while breastfeeding. B12 does transfer into breast milk and is essential for infant neurological development. The adequate intake for lactating women is 2.8 mcg/day per NIH. Women who exclusively breastfeed and follow a vegetarian or vegan diet are at higher risk for infant B12 deficiency and should supplement accordingly.

Pregnancy and Lactation Safety: What You Must Know Before Starting Retatrutide

Retatrutide is contraindicated in pregnancy. This is not a soft caution. It is the same class-level concern that applies to all GLP-1-based agents.

Rodent developmental toxicity studies for related GLP-1 receptor agonists have shown fetal growth restriction and skeletal abnormalities at exposures approximating clinical doses. These findings are summarized in the prescribing information for approved agents like semaglutide, and the same concern extends by mechanism to retatrutide. Because retatrutide is investigational, it has no FDA pregnancy category, but the risk profile is consistent with what regulators have called "may cause fetal harm" for this drug class.

ACOG guidance on obesity pharmacotherapy does not yet address triple agonists specifically because they were not approved at the time of writing, but the Society's general principle is to discontinue weight-loss pharmacotherapy before conception and to use effective contraception during treatment.

Contraception Requirement

If you are of reproductive potential, use highly effective contraception throughout retatrutide treatment and for at least two months after the last dose. This washout recommendation mirrors the class approach used for semaglutide (two months) as documented in the Wegovy prescribing information. Because retatrutide has a longer half-life and is still in trials, clinical teams often extend this to three months as a precaution.

GLP-1 agonists slow gastric emptying, which can reduce peak plasma concentrations of oral contraceptive pills, though the clinical significance for combined oral contraceptives appears modest based on pharmacokinetic sub-studies for semaglutide. A non-oral method (IUD, implant, or injectable) eliminates absorption variability entirely and is worth considering for women using retatrutide who need contraception.

B12 in Pregnancy

Whatever weight-loss journey brings you to retatrutide, you must discontinue it before trying to conceive. Once pregnant, B12 at adequate levels is non-negotiable. Severe maternal B12 deficiency has been associated with neural tube defects, early pregnancy loss, and intrauterine growth restriction. A 2017 cohort study in AJOG found that women in the lowest quartile of B12 at 10 to 12 weeks gestation had significantly higher rates of neural tube defect-affected pregnancies compared to women with adequate levels.

Who This Is Right For and Who Should Think Twice

Women Who May Benefit Most from Concurrent B12 Supplementation with Retatrutide

• Women with PCOS on metformin for one or more years
• Women over 50 accessing retatrutide through clinical trials
• Women with a vegetarian or vegan diet (dietary B12 is absent or low)
• Women with a prior history of gastric bypass (intrinsic factor production is reduced or absent)
• Women with symptoms of peripheral neuropathy of unclear cause

Women Who Need Extra Caution

• Women who are pregnant or planning pregnancy: stop retatrutide first, confirm B12 adequacy, begin prenatal vitamins.
• Women with pernicious anemia or confirmed intrinsic factor antibodies: oral B12 supplementation alone is insufficient; these women need intramuscular or high-dose sublingual B12 regardless of what other medications they take.
• Women on proton pump inhibitors (PPIs) in addition to metformin: PPIs reduce gastric acid, further impairing food-bound B12 absorption. The combination of PPI plus metformin plus age-related hypochlorhydria can produce rapid depletion.

Women for Whom This Entire Question Is Premature

Retatrutide is not FDA-approved. If you are pursuing it through a compounding pharmacy without trial enrollment, you are taking on the risks of an unapproved drug without the safety monitoring infrastructure of a clinical trial. A clinician who prescribes it should be providing structured follow-up, baseline labs including B12, and a clear plan for what happens if you need to stop.

Practical Supplement Guidance: Timing, Form, and Dose

There is no required time separation between vitamin B12 and retatrutide. Retatrutide is injected subcutaneously once weekly and enters the systemic circulation directly. Vitamin B12 taken orally follows the ileal intrinsic factor pathway. The two never compete at any absorption site.

• Form: Cyanocobalamin and methylcobalamin are both effective for most women. Methylcobalamin is the active form and may be preferred for women with MTHFR variants or neurological concerns, though high-quality comparative trial data showing clinical superiority in neurological outcomes is limited.
• Dose for general supplementation: 500 to 1,000 mcg oral daily covers most women who are not severely depleted.
• Dose for active deficiency on metformin: Start with 1,000 mcg oral daily and retest in 8 to 12 weeks. If levels do not rise adequately, shift to intramuscular dosing.
• Sublingual: High-dose sublingual B12 (1,000 to 2,000 mcg) can achieve adequate serum levels through passive diffusion even in women without functional intrinsic factor, making it a practical middle ground between oral and intramuscular routes.

B12 is water-soluble with no established tolerable upper limit. Taking more than you need is excreted in urine. Toxicity from B12 supplementation at standard doses has not been documented.